<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512451512</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512451512</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>New Perspectives</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ontaneda</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451512">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>LaRocca</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512451512">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Coetzee</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512451512">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451512">1</xref>
</contrib>
<on-behalf-of>On behalf of the NMSS MSFC Task Force listed in Appendix.</on-behalf-of>
</contrib-group>
<aff id="aff1-1352458512451512"><label>1</label>Mellen Center for MS Treatment and Research, Cleveland Clinic, USA</aff>
<aff id="aff2-1352458512451512"><label>2</label>National Multiple Sclerosis Society, USA</aff>
<author-notes>
<corresp id="corresp1-1352458512451512">Richard A. Rudick, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, U-10, Cleveland, OH, 44195, USA. Email: <email>rudickr@ccf.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>8</issue>
<fpage>1074</fpage>
<lpage>1080</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>4</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>This article describes proceedings from a meeting of the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures (the TF). The TF was appointed by the NMSS Research Programs Advisory Committee with the goal of pooling and analyzing existing datasets to explore the utility of novel disability outcome measures based on the Multiple Sclerosis Functional Composite (MSFC) approach. The TF seeks to determine the suitability of the MSFC approach as a primary clinical outcome measure for registration trials in MS. The TF met in Washington, DC, Dec. 14 and 15, 2011, and provided unanimous support for a collaborative approach involving representatives from academic medicine, the pharmaceutical industry, regulatory agencies, the NMSS and the Critical Path Institute. There was also unanimous agreement that analysis of existing datasets would be useful in making progress toward the objective. The TF placed high value on determining the clinical meaning of individual component measures for the MSFC, and in establishing optimal analysis methods for MSFC so that scores would be more interpretable than the originally recommended <italic>z</italic>-score method. The background for a collaborative project aimed at developing an improved disability outcome measure is described in this paper.</p>
</abstract>
<kwd-group>
<kwd>Outcome assessment</kwd>
<kwd>multiple sclerosis functional composite</kwd>
<kwd>biomarker</kwd>
<kwd>clinical trials</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512451512" sec-type="intro">
<title>Introduction</title>
<sec id="section2-1352458512451512">
<title>Background leading to Task Force (TF)</title>
<p>Significant progress has been made over the last 30 years in developing a better understanding of the course of multiple sclerosis (MS), applying magnetic resonance imaging (MRI) to clinical MS studies, and in developing tools to quantify neurological disability in MS. However, traditional outcome measures — relapses and the Kurtzke Expanded Disability Status Score (EDSS) — remain the only accepted primary clinical outcome measures for MS registration trials, despite well-described, generally acknowledged shortcomings. Attempts to supplant the traditional clinical outcome measures with newer measures have so far been unsuccessful. A universally accepted measurement instrument that is precise, reliable, easy to administer, captures the key neurological domains affected by MS, is sensitive at various levels of disability and that accurately reflects neurological and neuropsychological disability is still lacking. Contributing to the challenge is the fact that MS is largely subclinical in its early stages, where MRI demonstrates active and progressive disease despite a relative paucity of symptoms; has extremely heterogeneous clinical manifestations, making use of any particular clinical outcome measure problematic in an MS group; features extremely slow evolution of MS disability, often spanning decades; and is marked by variability in disease severity and course between MS patients. Furthermore, a clinical outcome measure useful in early stage MS may not be optimal for advanced stages.</p>
<p>The need for better clinical outcome measures is particularly urgent for progressive forms of MS, where there is a significant unmet need for effective therapies and for informative clinical trial designs. The development of improved clinical outcome measures for disability progression will be a major determinant of the ability to evaluate new therapies in the area of highest unmet need.</p>
<p>The National MS Society (NMSS) stimulated development of clinical trial outcome measures through workshops and related projects<sup><xref ref-type="bibr" rid="bibr1-1352458512451512">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458512451512">2</xref></sup> in the past and subsequently appointed its first Clinical Outcomes Assessment Task Force in 1996, which met on several occasions and concluded that there was a need for a composite measure that: 1) reflects the impact of therapy on progression of the disease, 2) is useful for measuring clinical change, 3) is multi-dimensional and 4) is reliable, valid and sensitive to change as well as being cost effective.<sup><xref ref-type="bibr" rid="bibr3-1352458512451512">3</xref></sup></p>
<p>The NMSS Clinical Outcomes Assessment Task Force recommended a Multiple Sclerosis Functional Composite (MSFC), which called for multiple functional performance measures combined into a single composite.<sup><xref ref-type="bibr" rid="bibr4-1352458512451512">4</xref></sup> That recommendation was based on analysis of 14 longitudinal studies that included 5457 MS patients.<sup><xref ref-type="bibr" rid="bibr5-1352458512451512">5</xref></sup> The composite included the timed 25-foot walk (T25FW) to measure leg function, the timed nine-hole peg test (9HPT) to measure upper extremity function, and the 3-second version of the paced auditory serial addition test-3 (PASAT) to measure neuropsychological function. The task force recommended that each component score be converted to a <italic>z</italic>-score by normalizing to a reference population, and that the three component <italic>z</italic>-scores be averaged to create a single composite score. Importantly, MSFC component scores are operationally defined, quantitative and highly reproducible. Unlike EDSS, MSFC scores are not dependent on subjective clinician ratings or on reported need for gait assistance.</p>
<p>In May 2011, another workshop on outcomes assessment in MS was held in Washington, DC, under the sponsorship of the International Clinical Trials Committee. Conclusions from the meeting included the need to improve EDSS, refine MSFC and explore other outcome approaches, including patient-reported outcomes.<sup><xref ref-type="bibr" rid="bibr6-1352458512451512">6</xref></sup> These conclusions were presented to the Research Programs Advisory Committee of the NMSS, which led to the formation of the current TF.</p>
</sec></sec>
<sec id="section3-1352458512451512">
<title>Current MSFC TF</title>
<p>The current TF was created with the goal of conducting research that would lead to one or more improved clinical disability measures to accelerate progress in future MS trials. The initial focus of this TF is to further refine the current MSFC approach to create one or more outcome tools that cover the range of disability in MS and are adequate from a regulatory perspective. Pooling and analysis of data that have been collected during the course of longitudinal studies was proposed as an approach to advancing this goal. Engagement of representatives from academia, industry, patient support groups and regulatory agencies was sought. A meeting was held in Washington, DC, Dec. 14 and 15, 2011, with 38 TF members (see <xref ref-type="app" rid="app1-1352458512451512">appendix</xref>). In addition to creating and analyzing a pooled dataset, sharing of data for use by the broader MS community was also proposed.</p>
<sec id="section4-1352458512451512">
<title>MSFC background</title>
<p>Background on MSFC was reviewed during the initial phase of the meeting. Validity of the MSFC has been examined in multiple studies correlating MSFC scores with other scores of disability and self-report measures. Composite MSFC scores show good correlation with EDSS scores.<sup><xref ref-type="bibr" rid="bibr7-1352458512451512">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458512451512">8</xref></sup> Studies that address clinical meaningfulness have compared MSFC to multiple self-report measures and consistently show that MSFS scores relate to the severity of patient-reported symptoms.<sup><xref ref-type="bibr" rid="bibr7-1352458512451512">7</xref>,<xref ref-type="bibr" rid="bibr9-1352458512451512">9</xref><xref ref-type="bibr" rid="bibr10-1352458512451512"/>–<xref ref-type="bibr" rid="bibr11-1352458512451512">11</xref></sup> MSFC scores have also been shown to predict EDSS scores and self-report measures of disability.<sup><xref ref-type="bibr" rid="bibr8-1352458512451512">8</xref>,<xref ref-type="bibr" rid="bibr12-1352458512451512">12</xref></sup> MSFC components have been studied independently and have demonstrated significant cross-sectional <sup><xref ref-type="bibr" rid="bibr13-1352458512451512">13</xref><xref ref-type="bibr" rid="bibr14-1352458512451512"/>–<xref ref-type="bibr" rid="bibr15-1352458512451512">15</xref></sup> as well as predictive correlations.<sup><xref ref-type="bibr" rid="bibr16-1352458512451512">16</xref></sup> For T25FW and 9HPT, worsening from baseline of 20% or more reliably indicates disability progression. Meaningful change in PASAT scores is less clear.<sup><xref ref-type="bibr" rid="bibr17-1352458512451512">17</xref></sup></p>
<p>Several reports of correlations between MSFC and imaging parameters in cross-sectional and longitudinal studies were reviewed. Measures of brain atrophy, T2 lesion volume and T1 black hole lesion volume were found to correlate with the MSFC composite and with its component scores.<sup><xref ref-type="bibr" rid="bibr18-1352458512451512">18</xref></sup> Brain atrophy measures, specifically brain parenchymal fraction, correlate better with MSFC than EDSS scores in longitudinal studies.<sup><xref ref-type="bibr" rid="bibr19-1352458512451512">19</xref></sup> In clinical trials, MSFC scores have been found to parallel MRI effects of several immunomodulatory agents.<sup><xref ref-type="bibr" rid="bibr11-1352458512451512">11</xref>,<xref ref-type="bibr" rid="bibr20-1352458512451512">20</xref>,<xref ref-type="bibr" rid="bibr21-1352458512451512">21</xref></sup></p>
</sec>
<sec id="section5-1352458512451512">
<title>Prior use of MSFC in clinical trials</title>
<p>MSFC has been used as an outcome measure in several clinical trials.<sup><xref ref-type="bibr" rid="bibr11-1352458512451512">11</xref>,<xref ref-type="bibr" rid="bibr20-1352458512451512">20</xref><xref ref-type="bibr" rid="bibr21-1352458512451512"/>–<xref ref-type="bibr" rid="bibr22-1352458512451512">22</xref></sup> Of note, the International MS Secondary Progressive Avonex Controlled Trial (IMPACT) used the MSFC as a primary outcome measure and found a statistically significant difference between intramuscular interferon β-1a and placebo MSFC scores at 24 months that was not accompanied by treatment effects on EDSS.<sup><xref ref-type="bibr" rid="bibr11-1352458512451512">11</xref></sup></p>
</sec>
<sec id="section6-1352458512451512">
<title>Concerns with MSFC</title>
<p>There are two concerns with using the MSFC as originally proposed as a primary outcome measure for MS clinical trials. The first relates to the MSFC components, and the second relates to analysis and interpretation issues. It is this latter concern that has most limited acceptance of MSFC by regulatory agencies as a primary clinical outcome measure.</p>
<p>The PASAT was initially proposed as a neuropsychological component for the MSFC as a simple, reliable and sensitive measure of cognitive function. However, there is considerable evidence of practice effects with repeated administration of the MSFC.<sup><xref ref-type="bibr" rid="bibr23-1352458512451512">23</xref><xref ref-type="bibr" rid="bibr24-1352458512451512"/><xref ref-type="bibr" rid="bibr25-1352458512451512"/>–<xref ref-type="bibr" rid="bibr26-1352458512451512">26</xref></sup> Continuous improvement in PASAT scores, in active and placebo arms of clinical trials, complicates interpretation of change. It also appears that the PASAT may be somewhat dependent on an individual’s mathematical abilities <sup><xref ref-type="bibr" rid="bibr27-1352458512451512">27</xref>,<xref ref-type="bibr" rid="bibr28-1352458512451512">28</xref></sup> and some neuropsychologists have voiced concerns regarding the difficulty of the test and aversive emotional reactions to it.<sup><xref ref-type="bibr" rid="bibr29-1352458512451512">29</xref></sup></p>
<p>The Symbol Digit Modalities Test (SDMT) has been proposed as a possible substitute for the PASAT given its reliability, sensitivity, ease of administration, self-paced nature and lack of arithmetic demands.<sup><xref ref-type="bibr" rid="bibr30-1352458512451512">30</xref><xref ref-type="bibr" rid="bibr31-1352458512451512"/><xref ref-type="bibr" rid="bibr32-1352458512451512"/><xref ref-type="bibr" rid="bibr33-1352458512451512"/>–<xref ref-type="bibr" rid="bibr34-1352458512451512">34</xref></sup> The SDMT may also be used to test cognition in the setting of disease-modifying therapy use and is a sensitive marker for cognitive change over time.<sup><xref ref-type="bibr" rid="bibr35-1352458512451512">35</xref><xref ref-type="bibr" rid="bibr36-1352458512451512"/>–<xref ref-type="bibr" rid="bibr37-1352458512451512">37</xref></sup> SDMT results are exceptionally reliable with repeated testing <sup><xref ref-type="bibr" rid="bibr38-1352458512451512">38</xref><xref ref-type="bibr" rid="bibr39-1352458512451512"/>–<xref ref-type="bibr" rid="bibr40-1352458512451512">40</xref></sup> and have also been found to correlate with a number of MRI-related outcomes.<sup><xref ref-type="bibr" rid="bibr41-1352458512451512">41</xref><xref ref-type="bibr" rid="bibr42-1352458512451512"/>–<xref ref-type="bibr" rid="bibr43-1352458512451512">43</xref></sup> A recent international task force for a brief cognitive assessment in MS has recommended the use of SDMT over PASAT on feasibility grounds.<sup><xref ref-type="bibr" rid="bibr44-1352458512451512">44</xref></sup> Potential drawbacks of SDMT include reliance on visual function<sup><xref ref-type="bibr" rid="bibr45-1352458512451512">45</xref></sup> or verbal responses,<sup><xref ref-type="bibr" rid="bibr46-1352458512451512">46</xref></sup> which may be abnormal in MS.</p>
<p>The lack of a component that measures visual function has been seen as a weakness of the MSFC.<sup><xref ref-type="bibr" rid="bibr47-1352458512451512">47</xref></sup> Low-contrast letter acuity testing (LCLA) has emerged as a rapid, reliable and easy-to-perform method for measuring vision in MS.<sup><xref ref-type="bibr" rid="bibr48-1352458512451512">48</xref></sup> LCLA has been proposed and tested as a fourth component of the MSFC.<sup><xref ref-type="bibr" rid="bibr49-1352458512451512">49</xref></sup> LCLA also has been shown to correlate with imaging metrics including brain atrophy<sup><xref ref-type="bibr" rid="bibr50-1352458512451512">50</xref></sup> and lesion burden.<sup><xref ref-type="bibr" rid="bibr51-1352458512451512">51</xref></sup> Additionally, LCLA appears to correlate well with patient-reported vision quality of life metrics.<sup><xref ref-type="bibr" rid="bibr52-1352458512451512">52</xref></sup> LCLA has been used in two phase III trials of MS and shows the ability to demonstrate treatment effects.<sup><xref ref-type="bibr" rid="bibr53-1352458512451512">53</xref></sup> Questions remain regarding the optimal contrast level (1.25% versus 2.5%), whether to test in a monocular or binocular manner,<sup><xref ref-type="bibr" rid="bibr54-1352458512451512">54</xref></sup> and how to interpret the clinical meaning of an observed change.</p>
<p>The second, and perhaps more important, concern related to using MSFC as a primary outcome measure relates to difficulty interpreting the meaning of changes in the composite MSFC score. In a longitudinal observational study, it was reported that different reference populations resulted in widely different weightings of the MSFC components.<sup><xref ref-type="bibr" rid="bibr55-1352458512451512">55</xref></sup> Also, composite MSFC scores will be dependent on the baseline characteristics of the study population, so even if the reference population were held constant, <italic>z</italic>-scores from one study could not be compared with another, and treatment effect sizes using the same drug would be expected to differ based on the entry population. The clinical meaning of a <italic>z</italic>-score change for individual MSFC components has not been determined. An additional area of uncertainty is the fact that all MSFC components receive an equal weight in the composite. The contribution of each component to disability may vary over the disease course, and differential weighting may be needed to account for these differences. Similarly, it has been observed that certain EDSS components may have ceiling and floor effects in patients with very mild or severe disease.</p>
<p>Therefore, much discussion at the meeting centered around possible analysis methods for MSFC component data. Analysis of the existing MSFC composite score is inherently complex, while analysis of individual components is much simpler. It was suggested that the meaning of change for each MSFC component be evaluated independently, and the definition of clinically meaningful change be established for each component. Subsequently, the optimal analysis approach should be developed so that all MSFC components could be used to determine efficacy in an MS clinical trial. An example of this approach was published through a post hoc analysis of data from the AFFIRM and SENTINEL trials.<sup><xref ref-type="bibr" rid="bibr8-1352458512451512">8</xref></sup></p>
<p>The meeting participants agreed that it was preferable to initially establish clinical meaning of the components of a new MSFC outcome measure, in an attempt to achieve acceptance from a regulatory perspective. Specifically, criterion validation would be established by demonstrating that a particular change in an MSFC component was accompanied by an interpretable change in some meaningful comparison measure, such as a patient-reported outcome measure. Use of more advanced analytical techniques would proceed in parallel to this more directed objective.</p>
</sec></sec>
<sec id="section7-1352458512451512">
<title>A path forward</title>
<p>In March 2004, the U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative (CPI) with a report: Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. This report ushered in a new era of “regulatory sciences,” in which use of biological and imaging markers and novel clinical outcome measures could be developed in such a way as to achieve regulatory agency acceptance, and in that way speed effective drug development. The CPI represented a national strategy for forming collaborations to transform the way FDA-regulated medical products are developed, evaluated and manufactured.<sup><xref ref-type="bibr" rid="bibr56-1352458512451512">56</xref></sup> In response to this initiative, the Critical Path Institute (C-Path) was created in 2005 as a private-public partnership to bring participants in the drug development enterprise together with academic leaders, regulatory authorities and patient advocacy groups to respond in the different areas of scientific development. One of the specific goals for C-Path is the development of more informative and effective biomarkers and clinical outcome measures. C-Path proposes to develop databases to validate outcome measures that are openly shared across the research enterprise. Clinical outcome assessments (COAs), under the umbrella of drug-development tools (DDTs), are eligible to go through a specific qualification process as determined by the FDA Center for Drug Evaluation and Research (CDER) in advance of deciding to rely on them in a critical drug-treatment study. Qualification is a conclusion that, within a stated context of use, a DDT can be relied on to have a specific interpretation and application in drug development and regulatory review. Once qualified, DDTs will be publicly available to be used in any drug development program for the qualified context of use.<sup><xref ref-type="bibr" rid="bibr57-1352458512451512">57</xref></sup></p>
<p>The DDT process is new to the entire field of medical science, so it is not surprising that COAs for MS have not gone through a qualification pathway to date. As new outcome measures that focus on MS disease progression are developed, they will need to be evaluated and tested, and should be qualified by the DDT qualification process. Engagement of other national/multinational regulatory agencies, such as the European Medicines Agency (EMA), will be needed early in the process to ensure perspectives from these groups are also gathered.</p>
</sec>
<sec id="section8-1352458512451512">
<title>TF plan</title>
<p>To align the objectives of the MSFC task force with a regulatory pathway, C-Path emerged as a viable mechanism to enable the TF project. C-Path was formed in alignment with the FDA’s CPI, and at present there are five consortia aimed at creating collaborations that advance scientific innovations to improve human health. All consortia share common goals of advancing knowledge by precompetitive sharing of data across diverse stakeholders to advance DDTs for regulatory approval. Leadership of C-Path has shown interest in expanding its efforts to include MS, and in supporting the TF goals of evaluating existing datasets that include MSFC components for eventual presentation to the FDA as a potential primary clinical outcome measure. The creation of a new Multiple Sclerosis Consortium (MSC) has been proposed by C-Path to the NMSS with the ultimate aim of obtaining FDA qualification of an MSFC clinical outcome assessment instrument as a primary endpoint in clinical trials. The MSC will include representatives from academia, industry, patient advocacy groups, regulatory agencies and other government agencies. The MSC will be co-directed by a C-Path director and an industry or academic MS leader chosen by the MSC Steering Committee. The MSC will be under the governance of the NMSS through the MSFC TF.</p>
<p>The MSC specific aims will include: 1) creation of MS therapeutic area data standards in collaboration with the Clinical Data Interchange Standards Consortium (CDISC) and drawing from the National Institute of Neurological Disorders and Stroke (NINDS) “common data elements”; 2) remapping of legacy MS clinical trial data into common MS therapeutic area data standards; 3) creation of an online MS database of aggregated, standardized clinical data, and making this resource publicly available to qualified researchers; 4) creation of scientific consensus on the optimal components for inclusion in a modified MSFC; and 5) advancement of a new clinical outcome assessment DDT based on the MSFC to the FDA for regulatory qualification. The ultimate goal of the MSC collaboration will be to accelerate MS clinical trial development and increase the probability of successful submissions of applications for new MS therapeutic interventions to the FDA and EMA.</p>
<sec id="section9-1352458512451512">
<title>TF consensus</title>
<p>During the meeting, TF members were polled on their opinions related to this project. Most members agreed that the MSFC could be a useful outcome measure in progressive MS trials and that further analysis and development of the MSFC is worthwhile. There was general consensus that the MSFC measures clinically meaningful domains; however, there were mixed views on the ability of the MSFC to measure clinically meaningful change. It was generally agreed that correlations with patient-reported outcomes are essential to establish clinical relevance. Most members agreed that a modification of the MSFC would improve its utility as an outcome measure. A majority of TF members recommended that substitution of PASAT with SDMT should be evaluated, and no member disagreed with the addition of LCLA. There was general consensus that <italic>z</italic>-scores were not sufficiently interpretable, and most agreed that analysis of the change of components was more useful than composite scores. Among industry representatives, most members agreed that there would be interest in this program, and that pharmaceutical companies would be potentially willing to invest resources in it. At the conclusion of the meeting an overwhelming majority (96%) agreed that general consensus had been reached on these major points during the TF discussions as described above.</p>
<p>The TF agreed on the following general plan to move forward: 1) identify informative datasets from academia and industry; 2) initiate a process for mapping variables and standard data elements through collaboration with C-Path and in format with CDISC — it was pointed out that this effort would integrate with the Common Data Element MS project initiated by the NINDS; and 3) analyze traditional and possible new MSFC components for inclusion in a new primary clinical outcome measure. The inclusion of robust patient-reported outcomes into this analysis will help validate the clinical meaning of the outcome measures. The TF also recommended a broad communication strategy targeted at industry, advocacy groups and academia, to engage these groups and create a commitment for a common tool with long-term benefits to the entire MS clinical trial enterprise.</p>
</sec>
</sec>
<sec id="section10-1352458512451512" sec-type="conclusions">
<title>Conclusions</title>
<list id="list1-1352458512451512" list-type="order">
<list-item><p>There remains a significant unmet need for a more precise, reliable, meaningful and treatment-sensitive outcome measure for progressive MS clinical trials that is acceptable from a regulatory perspective. There is widespread dissatisfaction with the EDSS as an outcome measure for progressive MS, and an alternative is needed.</p></list-item>
<list-item><p>There is general consensus that the MSFC approach has attractive features in that it is based on quantitative tests of neurological performance, rather than on clinician ratings.</p></list-item>
<list-item><p>There is considerable existing data to support an analysis project that may substantially lessen the need for expensive and time-consuming prospective studies. This data may be adequate to develop evidence sufficient to significantly advance toward qualification of a new primary clinical outcome measure.</p></list-item>
<list-item><p>There is a significant opportunity to employ advanced analysis methods to existing data and to make data available openly as a community resource.</p></list-item>
<list-item><p>The active engagement of all players within the research enterprise including industry, academia and patient advocacy is needed and will provide an opportunity for development of common goals and strategies.</p></list-item>
<list-item><p>Development of a database that is initially focused on MSFC would set the stage for follow-up projects aimed at developing patient-reported outcomes, imaging markers and biological markers of the MS disease process. Such a database will also facilitate advancing the field of personalized medicine approaches to MS.</p></list-item></list>
</sec>
</body>
<back>
<app-group>
<app id="app1-1352458512451512">
<title>Appendix</title>
<p>List of Task Force members</p>
<p>Dagmar Amtman, PhD* University of Washington</p>
<p>Laura Balcer, MD* University of Pennsylvania</p>
<p>Ralph Benedict, PhD* University of Buffalo</p>
<p>Robert Bermel, MD* Cleveland Clinic</p>
<p>Giampaolo Brichetto, MD, PhD* AISM (Italian MS Society)</p>
<p>Diego Cadavid, MD* Biogen-Idec</p>
<p>Peter Calabresi, MD Johns Hopkins University</p>
<p>Eric Chamot, PhD* University of Alabama</p>
<p>Peter Chin, MD* Novartis Pharmaceuticals</p>
<p>Timothy Coetzee, PhD* National MS Society</p>
<p>Jeffrey Cohen, MD Cleveland Clinic</p>
<p>Gary Cutter, PhD University of Alabama</p>
<p>Tammy Dellovade, PhD* EMD Serono, Inc</p>
<p>Gordon Francis, MD* Novartis Pharmaceuticals</p>
<p>Robert Glanzman, MD Roche</p>
<p>Myla Goldman, MD* University of Virginia</p>
<p>Andrew Goodman, MD* University of Rochester</p>
<p>Ed Holloway* MS Society of Great Britain and Northern Ireland</p>
<p>Lynn Hudson, PhD* CAMD/C-PATH</p>
<p>Denisa Hurtukova, MD Teva</p>
<p>Richard Kim, MD* Elan Corporation</p>
<p>Lauren Krupp, MD* Stony Brook University</p>
<p>Stephen Lake, ScD* Genzyme Corporation</p>
<p>Nicholas LaRocca, PhD* National MS Society</p>
<p>Karen Lee, PhD* MS Society of Canada</p>
<p>David Leppert, MD Roche</p>
<p>Fred Lublin, MD* Mt. Sinai School of Medicine</p>
<p>Aaron Miller, MD* Mt. Sinai School of Medicine</p>
<p>Deborah Miller, PhD* Cleveland Clinic</p>
<p>Ellen Mowry, MD* Johns Hopkins</p>
<p>Rob Naismith, MD* Washington University</p>
<p>Paul O’Connor, MD St. Michael’s Hospital</p>
<p>Daniel Ontaneda, MD* Cleveland Clinic</p>
<p>Michael Panzara, MD* Genzyme Corporation</p>
<p>John Petkau, PhD* University of British Columbia</p>
<p>Chris Polman, MD, PhD VU Medical Centre, Amsterdam</p>
<p>John Richert, MD* Biogen Idec</p>
<p>Richard Rudick, MD* Cleveland Clinic</p>
<p>Jacob Runyan, MSc* Acorda Therapeutics</p>
<p>Kersten Sharrock, MS* National MS Society</p>
<p>Kathy Smith* Fast Forward</p>
<p>Maria Pia Sormani, PhD* University of Genoa</p>
<p>Diane Stephenson, PhD* CAMD/C-PATH</p>
<p>Gustavo Suarez, MD Acorda</p>
<p>Bernard Uitdehaag, MD, PhD* VU University Medical Center</p>
<p>Ursula Utz, PhD National Institutes of Health</p>
<p>Marc Walton, MD, PhD* U.S. Food and Drug Administration</p>
<p>Paola Zaratin, PhD AISM (Italian MS Society)</p>
<p>*Present during December 2011 meeting</p>
</app>
</app-group>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding statement</label>
<p>The National Multiple Sclerosis Society provided financial and administrative support for the meeting leading to this report.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>Dr. Ontaneda has received speaking fees in the last year from Biogen Idec.</p>
<p>Dr. LaRocca and Dr. Coetzee have nothing to declare.</p>
<p>Dr. Rudick has received consulting or speaking fees in the last three years from Biogen Idec, Genzyme, Novartis and Pfizer/Wyeth.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512451512">
<label>1.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Herndon</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Multiple Sclerosis</article-title>. <conf-name>Proceedings of the International Conference on Therapeutic Trials in Multiple Sclerosis</conf-name>. <conf-loc>Grand Island, NY</conf-loc>, <conf-date>April 23–24, 1982</conf-date>. <source>Arch Neurol</source> <year>1983</year>; <volume>40</volume>: <fpage>666</fpage>.</citation>
</ref>
<ref id="bibr2-1352458512451512">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitaker</surname><given-names>JN</given-names></name>
<name><surname>McFarland</surname><given-names>HF</given-names></name>
<name><surname>Rudge</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Outcomes assessment in multiple sclerosis clinical trials: a critical analysis</article-title>. <source>Mult Scler</source> <year>1995</year>; <volume>1</volume>: <fpage>37</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512451512">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudick</surname><given-names>R</given-names></name>
<name><surname>Antel</surname><given-names>J</given-names></name>
<name><surname>Confavreux</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Clinical outcomes assessment in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>1996</year>; <volume>40</volume>: <fpage>469</fpage>–<lpage>479</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512451512">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudick</surname><given-names>R</given-names></name>
<name><surname>Antel</surname><given-names>J</given-names></name>
<name><surname>Confavreux</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force</article-title>. <source>Ann Neurol</source> <year>1997</year>; <volume>42</volume>: <fpage>379</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512451512">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cutter</surname><given-names>GR</given-names></name>
<name><surname>Baier</surname><given-names>ML</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>Development of a multiple sclerosis functional composite as a clinical trial outcome measure</article-title>. <source>Brain</source> <year>1999</year>; <volume>122</volume> (<issue>Pt 5</issue>): <fpage>871</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512451512">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<etal/>
</person-group>. <article-title>Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects</article-title>. <source>Lancet Neurol</source> <year>2012</year>; <volume>11</volume>: <fpage>467</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512451512">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>DM</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<name><surname>Cutter</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life</article-title>. <source>Arch Neurol</source> <year>2000</year>; <volume>57</volume>: <fpage>1319</fpage>–<lpage>1324</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512451512">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Assessing disability progression with the Multiple Sclerosis Functional Composite</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>984</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512451512">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costelloe</surname><given-names>L</given-names></name>
<name><surname>O’Rourke</surname><given-names>K</given-names></name>
<name><surname>McGuigan</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>255</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512451512">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozakbas</surname><given-names>S</given-names></name>
<name><surname>Cagiran</surname><given-names>I</given-names></name>
<name><surname>Ormeci</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2004</year>; <volume>218</volume>: <fpage>3</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512451512">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Cutter</surname><given-names>GR</given-names></name>
<name><surname>Fischer</surname><given-names>JS</given-names></name>
<etal/>
</person-group>. <article-title>Benefit of interferon beta-1a on MSFC progression in secondary progressive MS</article-title>. <source>Neurology</source> <year>2002</year>; <volume>59</volume>: <fpage>679</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512451512">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>DM</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<name><surname>Baier</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Factors that predict health-related quality of life in patients with relapsing–remitting multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2003</year>; <volume>9</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512451512">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaufman</surname><given-names>M</given-names></name>
<name><surname>Moyer</surname><given-names>D</given-names></name>
<name><surname>Norton</surname><given-names>J</given-names></name>
</person-group>. <article-title>The significant change for the timed 25-foot walk in the multiple sclerosis functional composite</article-title>. <source>Mult Scler</source> <year>2000</year>; <volume>6</volume>: <fpage>286</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512451512">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwid</surname><given-names>SR</given-names></name>
<name><surname>Goodman</surname><given-names>AD</given-names></name>
<name><surname>McDermott</surname><given-names>MP</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative functional measures in MS: what is a reliable change?</article-title> <source>Neurology</source> <year>2002</year>; <volume>58</volume>: <fpage>1294</fpage>–<lpage>1296</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512451512">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoogervorst</surname><given-names>EL</given-names></name>
<name><surname>Kalkers</surname><given-names>NF</given-names></name>
<name><surname>Cutter</surname><given-names>GR</given-names></name>
<etal/>
</person-group>. <article-title>The patient’s perception of a (reliable) change in the Multiple Sclerosis Functional Composite</article-title>. <source>Mult Scler</source> <year>2004</year>; <volume>10</volume>: <fpage>55</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512451512">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bosma</surname><given-names>LV</given-names></name>
<name><surname>Kragt</surname><given-names>JJ</given-names></name>
<name><surname>Knol</surname><given-names>DL</given-names></name>
<etal/>
</person-group>. <article-title>Clinical scales in progressive MS: predicting long-term disability</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>345</fpage>–<lpage>350</lpage>; <comment>Epub ahead of print 25 August 2011</comment>.</citation>
</ref>
<ref id="bibr17-1352458512451512">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bosma</surname><given-names>LV</given-names></name>
<name><surname>Kragt</surname><given-names>JJ</given-names></name>
<name><surname>Brieva</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?</article-title> <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>862</fpage>–<lpage>867</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512451512">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kalkers</surname><given-names>NF</given-names></name>
<name><surname>Bergers</surname><given-names>L</given-names></name>
<name><surname>de Groot</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Concurrent validity of the MS Functional Composite using MRI as a biological disease marker</article-title>. <source>Neurology</source> <year>2001</year>; <volume>56</volume>: <fpage>215</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512451512">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>E</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<name><surname>Cutter</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients</article-title>. <source>Mult Scler</source> <year>2000</year>; <volume>6</volume>: <fpage>373</fpage>–<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512451512">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cadavid</surname><given-names>D</given-names></name>
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Peng</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Clinical consequences of MRI activity in treated multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1113</fpage>–<lpage>1121</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512451512">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Radue</surname><given-names>EW</given-names></name>
<name><surname>O’Connor</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>387</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512451512">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balcer</surname><given-names>LJ</given-names></name>
<name><surname>Galetta</surname><given-names>SL</given-names></name>
<name><surname>Calabresi</surname><given-names>PA</given-names></name>
<etal/>
</person-group>. <article-title>Natalizumab reduces visual loss in patients with relapsing multiple sclerosis</article-title>. <source>Neurology</source> <year>2007</year>; <volume>68</volume>: <fpage>1299</fpage>–<lpage>1304</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512451512">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beatty</surname><given-names>WW</given-names></name>
<name><surname>Goretti</surname><given-names>B</given-names></name>
<name><surname>Siracusa</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Changes in neuropsychological test performance over the workday in multiple sclerosis</article-title>. <source>Clin Neuropsychol</source> <year>2003</year>; <volume>17</volume>: <fpage>551</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512451512">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bever</surname><given-names>CT</given-names><suffix>Jr</suffix></name>
<name><surname>Grattan</surname><given-names>L</given-names></name>
<name><surname>Panitch</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. <article-title>The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study</article-title>. <source>Mult Scler</source> <year>1995</year>; <volume>1</volume>: <fpage>165</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512451512">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Cutter</surname><given-names>GR</given-names></name>
<name><surname>Fischer</surname><given-names>JS</given-names></name>
<etal/>
</person-group>. <article-title>Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial</article-title>. <source>Arch Neurol</source> <year>2001</year>; <volume>58</volume>: <fpage>961</fpage>–<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512451512">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Fischer</surname><given-names>JS</given-names></name>
<name><surname>Bolibrush</surname><given-names>DM</given-names></name>
<etal/>
</person-group>. <article-title>Intrarater and interrater reliability of the MS functional composite outcome measure</article-title>. <source>Neurology</source> <year>2000</year>; <volume>54</volume>: <fpage>802</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512451512">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chronicle</surname><given-names>EP</given-names></name>
<name><surname>MacGregor</surname><given-names>E</given-names></name>
</person-group>. <article-title>Are PASAT scores related to mathematical ability?</article-title> <source>Neuropsychol Rehabil</source> <year>1998</year>; <volume>8</volume>: <fpage>273</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512451512">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hiscock</surname><given-names>M</given-names></name>
<name><surname>Caroselli</surname><given-names>JS</given-names></name>
<name><surname>Kimball</surname><given-names>LE</given-names></name>
</person-group>. <article-title>Paced serial addition: modality-specific and arithmetic-specific factors</article-title>. <source>J Clin Exp Neuropsychol</source> <year>1998</year>; <volume>20</volume>: <fpage>463</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512451512">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tombaugh</surname><given-names>TN</given-names></name>
</person-group>. <article-title>A comprehensive review of the Paced Auditory Serial Addition Test (PASAT)</article-title>. <source>Arch Clin Neuropsychol</source> <year>2006</year>; <volume>21</volume>: <fpage>53</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512451512">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deloire</surname><given-names>MS</given-names></name>
<name><surname>Bonnet</surname><given-names>MC</given-names></name>
<name><surname>Salort</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>How to detect cognitive dysfunction at early stages of multiple sclerosis?</article-title> <source>Mult Scler</source> <year>2006</year>; <volume>12</volume>: <fpage>445</fpage>–<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512451512">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strober</surname><given-names>L</given-names></name>
<name><surname>Englert</surname><given-names>J</given-names></name>
<name><surname>Munschauer</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>1077</fpage>–<lpage>1084</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512451512">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langdon</surname><given-names>D</given-names></name>
<name><surname>Amato</surname><given-names>M</given-names></name>
<name><surname>Boringa</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>891</fpage>–<lpage>898</lpage>; <comment>Epub ahead of print 21 December 2011</comment>.</citation>
</ref>
<ref id="bibr33-1352458512451512">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drake</surname><given-names>AS</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name><surname>Morrow</surname><given-names>SA</given-names></name>
<etal/>
</person-group>. <article-title>Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>228</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512451512">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brochet</surname><given-names>B</given-names></name>
<name><surname>Deloire</surname><given-names>MS</given-names></name>
<name><surname>Bonnet</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>1242</fpage>–<lpage>1249</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512451512">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmen</surname><given-names>C</given-names></name>
<name><surname>Piehl</surname><given-names>F</given-names></name>
<name><surname>Hillert</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>708</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512451512">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amato</surname><given-names>MP</given-names></name>
<name><surname>Portaccio</surname><given-names>E</given-names></name>
<name><surname>Goretti</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Relevance of cognitive deterioration in early relapsing–remitting MS: a 3-year follow-up study</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>1474</fpage>–<lpage>1482</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512451512">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrow</surname><given-names>SA</given-names></name>
<name><surname>O’Connor</surname><given-names>PW</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<etal/>
</person-group>. <article-title>Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>1385</fpage>–<lpage>1392</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512451512">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RH</given-names></name>
<name><surname>Duquin</surname><given-names>JA</given-names></name>
<name><surname>Jurgensen</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>940</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512451512">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrow</surname><given-names>SA</given-names></name>
<name><surname>O’Connor</surname><given-names>PW</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<etal/>
</person-group>. <article-title>Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>1385</fpage>–<lpage>1392</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512451512">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RH</given-names></name>
<name><surname>Smerbeck</surname><given-names>A</given-names></name>
<name><surname>Parikh</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials</article-title>. <source>Mult Scler</source>. <comment>Epub ahead of print 25 January 2012</comment>.</citation>
</ref>
<ref id="bibr41-1352458512451512">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stankiewicz</surname><given-names>JM</given-names></name>
<name><surname>Glanz</surname><given-names>BI</given-names></name>
<name><surname>Healy</surname><given-names>BC</given-names></name>
<etal/>
</person-group>. <article-title>Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis</article-title>. <source>J Neuroimaging</source> <year>2011</year>; <volume>21</volume>: <fpage>e50</fpage>–<lpage>e56</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512451512">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Houtchens</surname><given-names>MK</given-names></name>
<name><surname>Benedict</surname><given-names>RH</given-names></name>
<name><surname>Killiany</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Thalamic atrophy and cognition in multiple sclerosis</article-title>. <source>Neurology</source> <year>2007</year>; <volume>69</volume>: <fpage>1213</fpage>–<lpage>1223</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512451512">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bomboi</surname><given-names>G</given-names></name>
<name><surname>Ikonomidou</surname><given-names>VN</given-names></name>
<name><surname>Pellegrini</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis</article-title>. <source>J Neuroimaging</source> <year>2011</year>; <volume>21</volume>: <fpage>e57</fpage>-<lpage>e63</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512451512">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langdon</surname><given-names>D</given-names></name>
<name><surname>Amato</surname><given-names>M</given-names></name>
<name><surname>Boringa</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>891</fpage>–<lpage>898</lpage>; <comment>Epub ahead of print 21 December 2011</comment>.</citation>
</ref>
<ref id="bibr45-1352458512451512">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bruce</surname><given-names>JM</given-names></name>
<name><surname>Bruce</surname><given-names>AS</given-names></name>
<name><surname>Arnett</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS</article-title>. <source>J Int Neuropsychol Soc</source> <year>2007</year>; <volume>13</volume>: <fpage>544</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512451512">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnett</surname><given-names>PA</given-names></name>
<name><surname>Smith</surname><given-names>MM</given-names></name>
<name><surname>Barwick</surname><given-names>FH</given-names></name>
<etal/>
</person-group>. <article-title>Oralmotor slowing in multiple sclerosis: relationship to neuropsychological tasks requiring an oral response</article-title>. <source>J Int Neuropsychol Soc</source> <year>2008</year>; <volume>14</volume>: <fpage>454</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr47-1352458512451512">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
</person-group>. <article-title>The multiple sclerosis functional composite: a clinically meaningful measure of disability</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume> (<issue>Suppl 3</issue>): <fpage>S8</fpage>–<lpage>S15</lpage>.</citation>
</ref>
<ref id="bibr48-1352458512451512">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balcer</surname><given-names>LJ</given-names></name>
<name><surname>Frohman</surname><given-names>EM</given-names></name>
</person-group>. <article-title>Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume> (<issue>Suppl 3</issue>): <fpage>S16</fpage>–<lpage>S23</lpage>.</citation>
</ref>
<ref id="bibr49-1352458512451512">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balcer</surname><given-names>LJ</given-names></name>
<name><surname>Baier</surname><given-names>ML</given-names></name>
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite</article-title>. <source>Neurology</source> <year>2003</year>; <volume>61</volume>: <fpage>1367</fpage>–<lpage>1373</lpage>.</citation>
</ref>
<ref id="bibr50-1352458512451512">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baier</surname><given-names>ML</given-names></name>
<name><surname>Cutter</surname><given-names>GR</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis</article-title>. <source>Neurology</source> <year>2005</year>; <volume>64</volume>: <fpage>992</fpage>–<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr51-1352458512451512">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>GF</given-names></name>
<name><surname>Schwartz</surname><given-names>ED</given-names></name>
<name><surname>Lei</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Relation of vision to global and regional brain MRI in multiple sclerosis</article-title>. <source>Neurology</source> <year>2007</year>; <volume>69</volume>: <fpage>2128</fpage>–<lpage>2135</lpage>.</citation>
</ref>
<ref id="bibr52-1352458512451512">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mowry</surname><given-names>EM</given-names></name>
<name><surname>Loguidice</surname><given-names>MJ</given-names></name>
<name><surname>Daniels</surname><given-names>AB</given-names></name>
<etal/>
</person-group>. <article-title>Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2009</year>; <volume>80</volume>: <fpage>767</fpage>–<lpage>772</lpage>.</citation>
</ref>
<ref id="bibr53-1352458512451512">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balcer</surname><given-names>LJ</given-names></name>
<name><surname>Galetta</surname><given-names>SL</given-names></name>
<name><surname>Calabresi</surname><given-names>PA</given-names></name>
<etal/>
</person-group>. <article-title>Natalizumab reduces visual loss in patients with relapsing multiple sclerosis</article-title>. <source>Neurology</source> <year>2007</year>; <volume>68</volume>: <fpage>1299</fpage>–<lpage>1304</lpage>.</citation>
</ref>
<ref id="bibr54-1352458512451512">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pineles</surname><given-names>SL</given-names></name>
<name><surname>Birch</surname><given-names>EE</given-names></name>
<name><surname>Talman</surname><given-names>LS</given-names></name>
<etal/>
</person-group>. <article-title>One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis</article-title>. <source>Am J Ophthalmol</source> <year>2011</year>; <volume>152</volume>: <fpage>133</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr55-1352458512451512">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fox</surname><given-names>RJ</given-names></name>
<name><surname>Lee</surname><given-names>JC</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Optimal reference population for the multiple sclerosis functional composite</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>909</fpage>–<lpage>914</lpage>.</citation>
</ref>
<ref id="bibr56-1352458512451512">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woodcock</surname><given-names>J</given-names></name>
<name><surname>Woosley</surname><given-names>R</given-names></name>
</person-group>. <article-title>The FDA critical path initiative and its influence on new drug development</article-title>. <source>Annu Rev Med</source> <year>2008</year>; <volume>59</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr57-1352458512451512">
<label>57.</label>
<citation citation-type="gov">
<collab>U.S. Food and Drug Administration.</collab> <source>Drug Development Tools (DDT) Qualification Program [online]</source>, <comment><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm">http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm</ext-link></comment> (<year>2012</year>, <access-date>accessed 14 February 2012</access-date>).</citation>
</ref>
</ref-list>
</back>
</article>